BioCentury
ARTICLE | Clinical News

Scancell Holdings pl preclinical data

March 30, 2015 7:00 AM UTC

In a mouse model of melanoma, SCIB2 plus a murine CTLA-4 (CD152) immune checkpoint inhibitor increased tumor destruction and significantly improved survival vs. SCIB2 alone and CTLA-4 inhibition alon...